About the Conference

The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.

Venue Information

The Union League of Philadelphia 140 South Broad Street Philadelphia, PA 19102 Tel: (215) 405-9578 www.unionleague.org/ Add to your Calendar

Supporters

AZ-Bio-Logo-med

GeorgiaBIO

Who Should Attend

WhoShouldAttend

The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.

Industry News from BioCentury

  • Emergent, MorphoSys to co-develop MOR209/ES414MorphoSys AG (Xetra:MOR; Pink:MPSYF) partnered with Emergent BioSolutions Inc. (NYSE:EBS) to develop and commercialize ES414, a bispecific ADAPTIR antibody targeting prostate-specific membrane antigen (PSMA; FOLH1; GCPII) and CD3. The compound -- to be renamed MOR209/ES414 -- was shown in preclinical studies to cause T cells to attack prostate cancer cells expressing PSMA.

    The companies will jointly develop the compound with MorphoSys bearing 64% and Emergent 36% of the total costs. MorphoSys will gain worldwide commercialization rights excluding the U.S. and Canada, where Emergent will retain rights. Emergent will receive an upfront payment of $20 million and is eligible for up to $163 million in milestone payments. Emergent will receive low single digit royalties on product sales in MorphoSys's territories, and MorphoSys will receive tiered royalties from mid-single digits up to 20% on product sales in Emergent's territories.

    Emergent closed up $0.32 to $23.44 and MorphoSys closed up EUR 0.62 to EUR 70.13 on Tuesday.
Read more

Industry News from PharmAsia

  • COMMENT: What’s Really Behind Roche’s Interest In Chugai?Following initial mass media reports, speculation is rising that Roche may soon exercise an option to acquire the roughly 39% of Japanese firm Chugai that it does not already own. The possible reasons for such a deal are not clear cut however.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/7-tmagntaW4" height="1" width="1" />
Read more